Therapeutic Effects of Neuroactive Drugs on Hypothalamo-Pituitary in Man
The treatment of endocrine disorders by neuropharmacological manipulation is a therapeutic field that has only began to be exploited in the last twenty years, and continues to evolve rapidly. In 1947, it was first suggested by Green and Harris (1) that hypothalamic substances regulated hormone secretion from the anterior pituitary. Corticotropin-releasing factor was the first of these substances to be identified in a bioassay system, while in 1982 the most recent hypothalamic peptide, growth hormone releasing hormone (GHRH), was sequenced. Paralleling the identification of the hypothalamic peptides has been progress in understanding the complex interactions of the innervation of the hypothalamus. With this knowledge, and the concomitant availability of biosynthetic hypothalamic peptides, modulation of the secretion of prolactin, growth hormone (GH) and adrenocorticotropin by manipulation of the hypothalamic-pituitary axis has resulted in major therapeutic advances. This chapter will confine itself to the drugs relevant to these hormones, but excludes analogues of the hypothalamic peptides such as octreotide and the GnRH superagonists.
KeywordsGrowth Hormone Dopamine Agonist Growth Hormone Release Hormone Sodium Valproate Exogenous Growth Hormone
Unable to display preview. Download preview PDF.
- 5.Besser, G., Medical management of prolactinomas, In J.R. Givens (ed) Hormone-Secreting Pituitary Tumours ,Year Book Medical Publisher, Chicago, pp. 255–273 1982.Google Scholar
- 17.Votava, Z., and I. Lamplova, Antiserotonin activity of some ergolenyn and isoergolenyn derivatives in comparison with LSD and the influence of monoamine inhibiton of the serotonin effect, In E. Roshlin (ed) Neuropsychopharmacology II Elsevier/North, Amsterdam, pp. 68–73, 1961.Google Scholar
- 25.Vance, M.L., D.L. Kaiser, LA. Frohman, J. Rivier, W.W. Vale, and M.O. Thorner, Role of dopamine in the regulation of growth hormone secretion: dopamine and bromocriptine augment growth hormone (GH)-releasing hormone stimulated GH secretion in normal men, J Clin Endocrinol Metab 64:1136–1141, 1987.PubMedCrossRefGoogle Scholar
- 27.Chihara, K., H. Kodama, H. Kaji, T. Kita, Y. Kashio, Y. Okimura, H. Abe, and T. Fujita, Augmentation by propranolol of growth hormone-releasing hormone-(l-44)-NH2-induced growth hormone release in normal short and normal children, J Clin Endocrinol Metab 61: 229–233, 1985.PubMedCrossRefGoogle Scholar
- 30.Locatelli, V., A. Torsello, M. Redaelli, E. Ghigo, F. Massara, and E.E. Müller, Cholinergic agonists and antagonist drugs modulate the growth hormone response to growth hormone-releasing hormone in the rat: evidence for mediation by somatostatin, J Endocrinol 111: 271–278, 1986.PubMedCrossRefGoogle Scholar
- Dayanithi, G., and F. Antoni, Atriopeptins are potent inhibitors of corticotropin secretion by anterior pituitary cells in vitro: involvement of the -ANF receptor domain of membrane-bound cuanylate cyclase, Biochem Biophys Res Commun ,In Press.Google Scholar
- 40.Al-Damluji, S., S. Tomlin, L. Perry, P. Bouloux, A. Grossman, L.H. Rees and G. Besser, Alpha adrenoceptor stimulation of ACTH secretion by a specific central mechanism in man, J Endocrinol 104: 40, Abstract #48, 1985.Google Scholar
- 42.Mamplan, T., J. Blake Tyrell, and C.B. Wilson, Transsphenoidal microsurgery for Cushing’s disease, Ann Int Med 109: 487–493, 1988.Google Scholar
- Howlett, T., P. Plowman, J. Wass, L. Rees, A. Jones, and G. Besser, Megavoltage pituitary irradiation in the management of Cushing’s disease and Nelson’s syndrome, long-term follow-up, Clin Endocrinol ,In Press.Google Scholar
- 52.Avgerinos, P.C., L.K. Nieman, E.H. Oldfield, T. Loughlin, K.M. Barnes, D.L. Loriaux, and G.B. Cutler, Jr., The effect of pulsatile corticotrophin releasing hormone administration on the adrenal insufficiency that follows cure of Cushing’s disease, J Clin Endocrinol Metab 68: 912–916, 1989.PubMedCrossRefGoogle Scholar